Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
口服雌激素受体 PROTAC Vepdegestrant (ARV-471) 作为单一疗法以及与 CDK4/6 或 PI3K/mTOR 通路抑制剂联合使用在临床前 ER+ 乳腺癌模型中具有高效性
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-23-3465
Sheryl M Gough, John J Flanagan, Jessica Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Debbie Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John Corradi, Katherine Digianantonio, Ieva Drulyte, Ali